Zeneo® Midazolam Earns The Orphan Drug Designation
Source: Crossject
The American Food and Drug Administration (FDA) has granted Orphan Drug Designation to ZENEO® Midazolam for the treatment of status epilepticus (epileptic seizure lasting longer than 5 minutes).
The orphan designation for ZENEO® Midazolam improves Crossject’s international visibility and gives impetus to its current negotiations for partnerships with pharmaceutical laboratories.
-
Most popular related searches
Customer comments
No comments were found for Zeneo® Midazolam Earns The Orphan Drug Designation. Be the first to comment!